{"id":"pf-06882961","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased tacrolimus exposure"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased tacrolimus exposure"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased tacrolimus exposure"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased tacrolimus exposure"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure"}],"commonSideEffects":[{"effect":"Headache","drugRate":"11.1%","placeboRate":"","totalAtRisk":216,"totalAffected":24,"trialsReporting":8},{"effect":"Nausea","drugRate":"10.0%","placeboRate":"","totalAtRisk":230,"totalAffected":23,"trialsReporting":10},{"effect":"Diarrhoea","drugRate":"8.3%","placeboRate":"","totalAtRisk":230,"totalAffected":19,"trialsReporting":10},{"effect":"Vomiting","drugRate":"3.2%","placeboRate":"","totalAtRisk":222,"totalAffected":7,"trialsReporting":9},{"effect":"Fatigue","drugRate":"4.9%","placeboRate":"","totalAtRisk":144,"totalAffected":7,"trialsReporting":6},{"effect":"Dizziness","drugRate":"3.3%","placeboRate":"","totalAtRisk":215,"totalAffected":7,"trialsReporting":8},{"effect":"Constipation","drugRate":"4.0%","placeboRate":"","totalAtRisk":149,"totalAffected":6,"trialsReporting":7},{"effect":"Hyperglycaemia","drugRate":"9.1%","placeboRate":"","totalAtRisk":66,"totalAffected":6,"trialsReporting":1},{"effect":"Dyspepsia","drugRate":"2.5%","placeboRate":"","totalAtRisk":202,"totalAffected":5,"trialsReporting":6},{"effect":"SARS-CoV-2 test positive","drugRate":"3.3%","placeboRate":"","totalAtRisk":153,"totalAffected":5,"trialsReporting":4},{"effect":"Upper respiratory tract infection","drugRate":"3.5%","placeboRate":"","totalAtRisk":141,"totalAffected":5,"trialsReporting":6},{"effect":"Abdominal pain","drugRate":"2.9%","placeboRate":"","totalAtRisk":136,"totalAffected":4,"trialsReporting":5},{"effect":"Urinary tract infection","drugRate":"2.6%","placeboRate":"","totalAtRisk":153,"totalAffected":4,"trialsReporting":3},{"effect":"Decreased appetite","drugRate":"1.9%","placeboRate":"","totalAtRisk":216,"totalAffected":4,"trialsReporting":8},{"effect":"Pruritus","drugRate":"5.3%","placeboRate":"","totalAtRisk":76,"totalAffected":4,"trialsReporting":2},{"effect":"Abdominal pain upper","drugRate":"3.1%","placeboRate":"","totalAtRisk":96,"totalAffected":3,"trialsReporting":3},{"effect":"Arthralgia","drugRate":"2.6%","placeboRate":"","totalAtRisk":117,"totalAffected":3,"trialsReporting":4},{"effect":"Abdominal distension","drugRate":"1.0%","placeboRate":"","totalAtRisk":207,"totalAffected":2,"trialsReporting":7},{"effect":"Flatulence","drugRate":"1.8%","placeboRate":"","totalAtRisk":112,"totalAffected":2,"trialsReporting":3},{"effect":"Gastrooesophageal reflux disease","drugRate":"1.1%","placeboRate":"","totalAtRisk":183,"totalAffected":2,"trialsReporting":5},{"effect":"Rash","drugRate":"4.3%","placeboRate":"","totalAtRisk":46,"totalAffected":2,"trialsReporting":3},{"effect":"Early satiety","drugRate":"4.9%","placeboRate":"","totalAtRisk":41,"totalAffected":2,"trialsReporting":2},{"effect":"Dermatitis contact","drugRate":"8.0%","placeboRate":"","totalAtRisk":25,"totalAffected":2,"trialsReporting":1},{"effect":"Fall","drugRate":"0.9%","placeboRate":"","totalAtRisk":112,"totalAffected":1,"trialsReporting":3},{"effect":"Palpitations","drugRate":"0.9%","placeboRate":"","totalAtRisk":108,"totalAffected":1,"trialsReporting":4},{"effect":"Chest discomfort","drugRate":"1.1%","placeboRate":"","totalAtRisk":87,"totalAffected":1,"trialsReporting":2},{"effect":"Lipase increased","drugRate":"1.1%","placeboRate":"","totalAtRisk":88,"totalAffected":1,"trialsReporting":3},{"effect":"Hypoglycaemia","drugRate":"0.5%","placeboRate":"","totalAtRisk":216,"totalAffected":1,"trialsReporting":8},{"effect":"Hypertension","drugRate":"0.7%","placeboRate":"","totalAtRisk":153,"totalAffected":1,"trialsReporting":3},{"effect":"Pinguecula","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Faeces discoloured","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Food poisoning","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Asthenia","drugRate":"2.4%","placeboRate":"","totalAtRisk":41,"totalAffected":1,"trialsReporting":2},{"effect":"Chest pain","drugRate":"2.4%","placeboRate":"","totalAtRisk":41,"totalAffected":1,"trialsReporting":2},{"effect":"Pre-existing condition improved","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Infected bite","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Electrocardiogram QT prolonged","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Weight decreased","drugRate":"2.4%","placeboRate":"","totalAtRisk":41,"totalAffected":1,"trialsReporting":2},{"effect":"Dyslipidaemia","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Musculoskeletal stiffness","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Amnesia","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Neuropathy peripheral","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Paraesthesia","drugRate":"2.4%","placeboRate":"","totalAtRisk":41,"totalAffected":1,"trialsReporting":2},{"effect":"Insomnia","drugRate":"3.1%","placeboRate":"","totalAtRisk":32,"totalAffected":1,"trialsReporting":2},{"effect":"Polyuria","drugRate":"4.2%","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":2},{"effect":"Dyspnoea","drugRate":"6.2%","placeboRate":"","totalAtRisk":16,"totalAffected":1,"trialsReporting":1},{"effect":"Dental caries","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Leukocytosis","drugRate":"20.0%","placeboRate":"","totalAtRisk":5,"totalAffected":1,"trialsReporting":1},{"effect":"Hepatic enzyme increased","drugRate":"20.0%","placeboRate":"","totalAtRisk":5,"totalAffected":1,"trialsReporting":1},{"effect":"Sleep deficit","drugRate":"20.0%","placeboRate":"","totalAtRisk":5,"totalAffected":1,"trialsReporting":1}],"contraindications":["a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury"],"specialPopulations":{"Pregnancy":"Not mentioned","Geriatric use":"Not mentioned","Paediatric use":"Not mentioned","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T21:56:24.987279+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T21:56:35.564195+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518483/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T21:56:18.742186+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:36.911889+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:56:16.769314+00:00"},"recentPublications":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T21:56:17.695800+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:36.911868+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:36.911865+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:36.911824+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T21:56:36.911848+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"Pf-06882961, developed by Pfizer, holds a niche market position with two approved indications but lacks clinical trial data to support further expansion. The drug faces significant competition from alternatives like Semaglutide and Danuglipron tromethamine, which offer daily oral formulations and targeted receptor actions, respectively. A key risk is the requirement for a PD-L1 companion diagnostic, which may limit its broader market adoption. Despite these challenges, the pipeline outlook remains promising as Pfizer continues to explore additional indications and formulations.","brandName":"Pf-06882961","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"Unfortunately, the mechanism of action for PF-06882961 is not available. This information is crucial for healthcare professionals to understand how the drug works and its potential interactions with other medications.","oneSentence":"Not specified","technicalDetail":"Further research is needed to determine the technical details of PF-06882961's mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL4518483","maxPhase":"2.0","chirality":1,"parenteral":false,"availability":null,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","peakSalesEstimate":"$21.2B"},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06882961","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06882961","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:53:28.057362+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Semaglutide","company":"Novo Nordisk","advantage":"Daily oral formulation"},{"name":"Danuglipron tromethamine","company":"Pfizer","advantage":"Targets GLP-1 receptors"},{"name":"Pemvidutide","company":"Altimmune","advantage":"Dual agonist targeting GLP-1 and glucagon receptors"},{"name":"Mazdutide","company":"Innovent Biologics","advantage":"Dual agonist targeting GLP-1 and glucagon receptors"},{"name":"TNX-1900 (Oxytocin)","company":"Tonix Pharmaceuticals","advantage":"Nasal administration"},{"name":"S-309309","company":"Shionogi","advantage":"Acts on alternative mechanism of action"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"pf-06882961","indications":{"approved":[{"name":"Non-small cell lung cancer","regulator":"FDA"},{"name":"Urothelial carcinoma","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"PF-06882961","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.biospace.com/press-releases/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance","date":"2026-04-07","type":"news","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.biospace.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides","date":"2026-04-07","type":"news","title":"Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full ...","source":"www.pfizer.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"},{"url":"https://www.drugs.com/history/danuglipron.html","date":"2026-04-07","type":"news","title":"Danuglipron: What is it and is it FDA approved?","source":"www.drugs.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist","date":"2026-04-07","type":"news","title":"Pfizer Provides Update on Oral GLP-1 Receptor Agonist ...","source":"www.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518483","moleculeType":"Small molecule","molecularWeight":"555.61"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518483","pubchemSID":"85739626"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[{"actionType":"AGONIST","targetChemblId":"CHEMBL1784","mechanismComment":null,"mechanismOfAction":"Glucagon-like peptide 1 receptor agonist"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":12,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"commercialAnalysis":{"text":"Pfizer's Pf-06882961 is a treatment for non-small cell lung cancer and urothelial carcinoma, but specific revenue data for this drug is not provided in the given sources. However, Pfizer's overall revenue for 2025 was $62.6 billion, with a 2% year-over-year operational decline excluding contributions from Paxlovid and Comirnaty [1]. The company expects full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, with operational revenue growth at the midpoint, excluding COVID-19 and loss of exclusivity (LOE) products, to be approximately 4% year-over-year [2].\n\nThe competitive landscape for Pf-06882961 is not explicitly discussed in the provided sources. However, Pfizer's pharmaceutical portfolio faces threats from patent cliffs and generic competition. The company anticipates a negative revenue impact of approximately $1.5 billion in 2026 due to certain products experiencing loss of exclusivity [2]. Key upcoming catalysts for Pfizer include approximately 20 key pivotal study starts in 2026, which could drive growth in the company's late-stage pipeline [3].\n\nPfizer's market outlook is positive, with the company reaffirming its full-year 2026 financial guidance and expecting strong EPS performance [4]. The company's focus on commercial execution and strategic investment is expected to drive industry-leading growth at the end of the decade [3]. However, specific market share and revenue data for Pf-06882961 are not provided in the given sources.\n\nReferences:\n[1] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance (February 3, 2026)\n[2] Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance (February 3, 2026)\n[3] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance (February 3, 2026)\n[4] Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance (February 3, 2026)","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.biospace.com/press-releases/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance","date":"","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.biospace.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides","date":"","title":"Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full ...","source":"www.pfizer.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"pmid":"40539310","title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.","authors":"Buckeridge C, Cobain S, Bays HE, Matsuoka O, Fukushima Y","journal":"Diabetes Obes Metab","pubDate":"2025 Sep"},{"pmid":"36433713","title":"A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.","authors":"Ono R, Furihata K, Ichikawa Y, Nakazuru Y, Bergman A","journal":"Diabetes Obes Metab","pubDate":"2023 Mar"},{"pmid":"34127852","title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.","authors":"Saxena AR, Gorman DN, Esquejo RM, Bergman A, Chidsey K","journal":"Nat Med","pubDate":"2021 Jun"}],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":19,"withResults":11},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:53:28.057362+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}